These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 36162766)

  • 1. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
    Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
    Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
    He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
    ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
    Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
    ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
    Singh D
    AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sono-Controllable and ROS-Sensitive CRISPR-Cas9 Genome Editing for Augmented/Synergistic Ultrasound Tumor Nanotherapy.
    Pu Y; Yin H; Dong C; Xiang H; Wu W; Zhou B; Du D; Chen Y; Xu H
    Adv Mater; 2021 Nov; 33(45):e2104641. PubMed ID: 34536041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
    Tao Y; Yi K; Hu H; Shao D; Li M
    J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
    Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
    Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo.
    Ibraheim R; Song CQ; Mir A; Amrani N; Xue W; Sontheimer EJ
    Genome Biol; 2018 Sep; 19(1):137. PubMed ID: 30231914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms.
    Dong Z; Qin Q; Hu Z; Chen P; Huang L; Zhang X; Tian T; Lu C; Pan M
    Virol Sin; 2019 Aug; 34(4):444-453. PubMed ID: 31218589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.
    Huang K; Zapata D; Tang Y; Teng Y; Li Y
    Biomaterials; 2022 Dec; 291():121876. PubMed ID: 36334354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-mediated genome editing in sea urchins.
    Lin CY; Oulhen N; Wessel G; Su YH
    Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.